Natalia Neparidze MD

Hematologic Oncology

Associate Professor Research DART Leader, Multiple Myeloma and Gammopathies Program Section of Hematology/Department of Internal Medicine and Yale Cancer Center Yale University School of Medicine

Join to view full profile

333 Cedar St# WWW403New Haven, CT 06510
Phone+1 203-785-4144
Fax+1 203-785-7232

Dr. Neparidze is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Neparidze's full profile Already have an account?

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Yale-New Haven Medical CenterResidency, Internal Medicine, 2004 - 2007
"Aieti" Highest Medical SchoolClass of 2000

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2010 - 2026
NY State Medical License 2010 - 2015
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016

Clinical Trials

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma Start of enrollment: 2022 Feb 21
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Start of enrollment: 2024 Jul 23
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Cumulative Antigen Suppression Reduces Clonal Plasma Cell Evolution in Gaucher Disease.
Noor Ul Ain, Noffar Bar, Lilu Guo, Katherine Klinger, Punita Gupta
American Journal of Hematology. 2026-09-01
Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study.
Ishfaq Ahmad, Rong Wang, Natalia Neparidze, Jane Lange, Shi-Yi Wang
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01
Treatment patterns for patients with initial diagnosis of smoldering multiple myeloma in the United States: a SEER-Medicare analysis.
Rong Wang, Sylvia H Hsu, Natalia Neparidze, Martin W Schoen, Su-Hsin Chang
Haematologica. 2026-07-16

Abstracts/Posters

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...
Natalia Neparidze, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019